Satellos Bioscience Brief: Adds "On Track: to Dose First Participant in Phase 1 Clinical Trial With SAT-3247 in Q3 2024; Cites Cash Balance of $27.7 Million at June 30, 2024
Satellos Bioscience Brief: Adds "On Track: to Dose First Participant in Phase 1 Clinical Trial With SAT-3247 in Q3 2024; Cites Cash Balance of $27.7 Million at June 30, 2024
Satellos生物科技簡報：計劃於2024年第三季度給予第一名參與者SAt-3247的第一階段臨床試驗劑量，並在現金餘額中引用2024年6月30日的$2770萬。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。